Oncology Fellowship

Gynecologic Oncology Fellowship Faculty Publications

Peer Reviewed Publications

Kim JS, Liang MI, Prendergast EN, Alldredge J, Datta A, Hurteau JA, Kirschner CV, Rodriguez G, Vogel TJ, Brooks RA, Cass I, Cohen JG, Penner KR, Wang CE, Diaz Moore ES.Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.Int J Gynecol Cancer. 2019 Sep;29(7):1156-1163. doi: 10.1136/ijgc-2019-000374. Epub 2019 Jul 27.  PMID: 31352365

Kim JS, Turbov J, Rosales R, Thaete LG, Rodriguez GC. Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth.Gynecol Oncol. 2019 Aug;154(2):432-440. doi: 10.1016/j.ygyno.2019.05.022. Epub 2019 Jun 6. PMID: 31178149

Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME
Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer. 
Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782
PMID:28708786

Kim JS, Ward KK, Shah NS, Saenz CC, McHale MT, Plaxe SC. Effects of obesity and hysterectomy approach on the surgical management of uterine malignancy. Am J Clin Exp Obstet Gynecol 2015;2(3):96-101.

 

Kim JS, Liang MI, Prendergast EN, Alldredge J, Datta A, Hurteau JA, Kirschner CV, Rodriguez G, Vogel TJ, Brooks RA, Cass I, Cohen JG, Penner KR, Wang CE, Diaz Moore ES.Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.Int J Gynecol Cancer. 2019 Sep;29(7):1156-1163. doi: 10.1136/ijgc-2019-000374. Epub 2019 Jul 27.  PMID: 31352365

Lengmang S, Shephard S, Datta A, Lozo S, Kirschner CV.
Pubovesical sling for residual incontinence after successful vesicovaginal fistula closure: a new approach to an old procedure.
Int Urogynecol J. 2018 Oct;29(10):1551-1556. doi: 10.1007/s00192-018-3582-x. Epub 2018 Feb 21
PMID: 29468331

Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME
Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer. 
Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782
PMID:28708786

Shephard SN, Lengmang SJ, Anzaku SA, Mamven OV, Kirschner CV.
Effect of HIV infection on outcomes after surgical repair of genital fistula.
Int J Gynaecol Obstet. 2017 Sep;138(3):293-298. doi: 10.1002/ijgo.12233. Epub 2017 Jun 28
PMID 28602050 .

Shephard SN, Lengmang SJ, Kirschner CV Bladder stones in vesicovaginal fistula: is concurrent repair an option? Experience with 87 patients. Int Urogynecol J. 2017 Apr;28(4):569-574. doi: 10.1007/s00192-016-3142-1. Epub 2016 Sep 17. PMID: 27640063

Kirschner CV, Lengmang SJ, Zhou Y, Chima GA, Karshima JA, Arrowsmith S. Urinary diversion for patients with inoperable obstetric vesicovaginal fistula: the Jos, Nigeria experience. Int Urogynecol J. 2016 Jun;27(6):865-70. doi: 10.1007/s00192-015-2871-x. Epub 2015 Nov 2. PMID:26527458

Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun;137(3):485-9.

Peterson CE, Rauscher GH, Johnson TP, Kirschner CV, Freels S, Barrett RE, Kim S, Fitzgibbon ML, Joslin CE, Davis FG.The effect of neighborhood disadvantage on the racial disparity in ovarian cancer-specific survival in a large hospital-based study in cook county, illinois.Front Public Health. 2015 Jan 22;3:8

Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer.CA Cancer J Clin. 2019 Jul;69(4):258-279. doi: 10.3322/caac.21561. Epub 2019 May 10. Review.                                                                                                                                                                        PMID: 31074865

Hoppenot C, Peters P, Cowan M, Moore ED, Hurteau J, Lee NK, Yamada SD. Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?        Gynecol Oncol. 2019 Jul;154(1):177-182. doi: 10.1016/j.ygyno.2019.04.681. Epub 2019 May 2.                                                                                                                                                PMID: 31056111

Ross JGC, Escamilla V, Lee NK, Diane Yamada S, Lindau ST.Geospatial patterns of access to self-care resources for obesity among endometrial cancer survivors in a high poverty urban community.Gynecol Oncol. 2019 Feb;152(2):322-327. doi: 10.1016/j.ygyno.2018.12.005. Epub 2018 Dec 20.                                                                                                      PMID: 30581035

Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME
Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer. 
Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782
PMID:28708786

Feng CH, Miller CM, Tenney ME, Lee NK, Yamada SD, Hasan Y. Statin Use Significantly Improves Overall Survival in High-Grade Endometrial Cancer. Int J Gynecol Cancer. 2016 Nov;26(9):1642-1649. PMID: 27654261

Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun;137(3):485-9

Kennedy V, Abramsohn E, Makelarski J, Barber R, Wroblewski K, Tenney M, Lee NK, Yamada SD, Lindau ST. Can you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation. Gynecol Oncol. 2015 Apr;137(1):119-24

Kenny HA, Lal-Nag M, Shen M, Kara B, Nahotko DA, Wroblewski K, Fazal S, Chen S, Chiang CY, Chen YJ, Brimacombe KR, Marugan J, Ferrer M, Lengyel EQuantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis. Mol Cancer Ther. 2020 Jan;19(1):52-62. doi: 10.1158/1535-7163.MCT-19-0052. Epub 2019 Sep 27. PMID: 31562255

Zhang Z, Zhan Q, Eckert M, Zhu A, Chryplewicz A, De Jesus DF, Ren D, Kulkarni RN, Lengyel E, He C, Chen M. RADAR: differential analysis of MeRIP-seq data with a random effect model. Genome Biol. 2019 Dec 23;20(1):294. doi: 10.1186/s13059-019-1915-9. PMID: 31870409

Hart PC, Kenny HA, Grassl N, Watters KM, Litchfield LM, Coscia F, Blaženović I, Ploetzky L, Fiehn O, Mann M, Lengyel E, Romero IL. Mesothelial Cell HIF1α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. Cell Rep. 2019 Dec 17;29(12):4086-4098.e6. doi: 10.1016/j.celrep.2019.11.079. PMID: 31851935

Ko SY, Lee W, Kenny HA, Dang LH, Ellis LM, Jonasch E, Lengyel E, Naora H.Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019 Oct 18;2(1):386. doi: 10.1038/s42003-019-0609-x. PMID: 31925178

Ko SY, Lee W, Kenny HA, Dang LH, Ellis LM, Jonasch E, Lengyel E, Naora H.Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019 Oct 18;2:386. doi: 10.1038/s42003-019-0609-x. eCollection 2019.  PMID: 31646189

Li G, Eckert MA, Chang JW, Montgomery JE, Chryplewicz A, Lengyel E, Moellering RE. Ultrasensitive, multiplexed chemoproteomic profiling with soluble activity-dependent proximity ligation. Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21493-21500. doi: 10.1073/pnas.1912934116. Epub 2019 Oct 7. PMID: 31591248

Dauer P, Lengyel ENew Roles for Glycogen in Tumor Progression. Trends Cancer. 2019 Jul;5(7):396-399. doi: 10.1016/j.trecan.2019.05.003. Epub 2019 May 31.  PMID: 31311654

…Lavarone C, Lengyel ER…,Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5. PMID: 30835824

McGuire S, Kara B, Hart PC, Montag A, Wroblewski K, Fazal S, Huang XY, Lengyel E, Kenny HA.Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis.  Gynecol Oncol. 2019 May;153(2):405-415. doi: 10.1016/j.ygyno.2019.01.020. Epub 2019 Feb 20. PMID: 30797592

Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blaženović I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor SM, Andrade J, Fiehn O, Moellering RE, Mann M, Lengyel EProteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 May;569(7758):723-728. doi: 10.1038/s41586-019-1173-8. Epub 2019 May 1. PMID: 31043742

Hart PC, Chiyoda T, Liu X, Weigert M, Curtis M, Chiang CY, Loth R, Lastra R, McGregor SM, Locasale JW, Lengyel E, Romero IL. SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019 Apr;17(4):870-881. doi: 10.1158/1541-7786.MCR-18-0409. Epub 2019 Jan 17. PMID: 30655321

Chryplewicz A, Tienda SM, Nahotko DA, Peters PN, Lengyel E, Eckert MA. Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. Sci Rep. 2019 Mar 26;9(1):5195. doi: 10.1038/s41598-019-41352-5. PMID: 30914657

Chapel DB, Lengyel E, Ritterhouse LL, Lastra RR. Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report. Int J Gynecol Pathol. 2019 Feb 21. doi: 10.1097/PGP.0000000000000594. [Epub ahead of print] PMID: 30807370

Lee W, Ko SY, Mohamed MS, Kenny HA, Lengyel E, Naora H. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019 Jan 7;216(1):176-194. doi: 10.1084/jem.20181170. Epub 2018 Dec 19. PMID: 30567719

Javellana M, Hoppenot C, Lengyel E
The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31404-5. doi: 10.1016/j.ygyno.2018.11.007. [Epub ahead of print]
PMID: 30471899

Loessner D, Rockstroh A, Shokoohmand A, Holzapfel BM, Wagner F, Baldwin J, Boxberg M, Schmalfeldt B, Lengyel E, Clements JA, Hutmacher DW.
A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns.
Biomaterials. 2018 Oct 16;190-191:63-75. doi: 10.1016/j.biomaterials.2018.10.014. [Epub ahead of print]
PMID:30396040

Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, Johnson A, Wroblewski K, Montag A, Yamada SD, López-Méndez B, Nilsson J, Mund A, Mann M, Curtis M.
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.
Cell. 2018 Sep 20;175(1):159-170.e16. doi: 10.1016/j.cell.2018.08.065.
PMID:30241606

Curtis M, Kenny HA, Ashcroft B, Mukherjee A, Johnson A, Zhang Y, Helou Y, Batlle R, Liu X, Gutierrez N, Gao X, Yamada SD, Lastra R, Montag A, Ahsan N, Locasale JW, Salomon AR, Nebreda AR, Lengyel E.
Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.
Cell Metab. 2018 Aug 28. pii: S1550-4131(18)30508-4. doi: 10.1016/j.cmet.2018.08.007. [Epub ahead of print]
PMID: 30174305

Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, Tienda SM, Chryplewicz A, Zhu AC, Yang Y, Huang JT, Chen SM, Xu ZG, Leng XH, Yu XC, Cao J, Zhang Z, Liu J, Lengyel E, He C.
m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer.
Nat Cell Biol. 2018 Sep;20(9):1074-1083. doi: 10.1038/s41556-018-0174-4. Epub 2018 Aug 27.
PMID: 30154548

Curtis M, Mukherjee A, Lengyel E.
The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis.
Trends Cancer. 2018 Aug;4(8):517-519. doi: 10.1016/j.trecan.2018.06.002. Epub 2018 Jun 22.
PMID: 30064659
.
Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y, Harada M, Kiyotani K, Lengyel E, Fleming GF, Nakamura Y
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
Clin Cancer Res. 2018 Nov 1;24(21):5357-5367. doi: 10.1158/1078-0432.CCR-18-0142. Epub 2018 May 2.
PMID: 29720506

Lengyel E, Makowski L, DiGiovanni J, Kolonin MG
Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors.
Trends Cancer. 2018 May;4(5):374-384. doi: 10.1016/j.trecan.2018.03.004. Epub 2018 Apr 5. Review.
PMID:29709261

Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, Yamada SD, Abumrad NA, Lengyel E.
Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
Oncogene. 2018 Apr;37(17):2285-2301. doi: 10.1038/s41388-017-0093-z. Epub 2018 Feb 5.
PMID:29398710

Li G, Montgomery JE, Eckert MA, Chang JW, Tienda SM, Lengyel E, Moellering RE
An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells.
Nat Commun. 2017 Nov 24;8(1):1775. doi: 10.1038/s41467-017-01854-0.
PMID:29176560

Hoppenot C, Eckert MA, Tienda SM, Lengyel E
Who are the long-term survivors of high grade serous ovarian cancer?
Gynecol Oncol. 2018 Jan;148(1):204-212. doi: 10.1016/j.ygyno.2017.10.032. Epub 2017 Nov 8. Review.
PMID: 29128106

Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.
Gynecol Oncol. 2017 Jul;146(1):153-160. doi: 10.1016/j.ygyno.2017.04.012. Epub 2017 Apr 26.
PMID:28456378

Lal-Nag M, McGee L, Guha R, Lengyel E, Kenny HA, Ferrer M
A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth.
SLAS Discov. 2017 Jun;22(5):494-506. doi: 10.1177/2472555216687082. Epub 2017 Jan 31

Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF.High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017 Apr 26. pii: S0090-8258(17)30793-X. . [Epub ahead of print] PMID:28456378

Lal-Nag M, McGee L, Guha R, Lengyel E, Kenny HA, Ferrer M.A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. SLAS Discov. 2017 Jun;22(5):494-506. doi: 10.1177/2472555216687082. Epub 2017 Jan 31. PMID: 28346091

Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero ILLoss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. . Cancer Prev Res (Phila). 2017 Apr;10(4):255-266. Epub 2017 Mar 6.
PMID: 28264838

Mukherjee A, Kenny HA, Lengyel E Unsaturated Fatty Acids Maintain Cancer Cell Stemness.
Cell Stem Cell. 2017 Mar 2;20(3):291-292. doi: 10.1016/j.stem.2017.02.008. PMID: 28257705

Sundaram KM, Zhang Y, Mitra AK, Kouadio JK, Gwin K, Kossiakoff AA, Roman BB, Lengyel E Piccirilli JA Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. Cancer Res. 2017 Apr ;77(7):1684-1696. Epub 2017 Feb 15. PMID: 28202518

Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel EGenomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 Dec;6(12):1342-1351. Epub 2016 Oct 7. PMID: 27856443

Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Morishige KI, Kurachi H, Lengyel E, Kimura T Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells.
Mol Cancer Res. 2017 Jan;15(1):78-92.. Epub 2016 Oct 6. PMID: 27758876

Liu X, Romero IL, Litchfield LM, Lengyel E, Locasale JW. Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers.
Cell Metab. 2016 Nov 8;24(5):728-739. Epub 2016 Oct 13. PMID: 27746051

Coscia F, Watters KM, Curtis M, Eckert MA, Chiang CY, Tyanova S, Montag A, Lastra RR, Lengyel E, Mann M. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Nat Commun. 2016 Aug 26;7:12645. doi: 10.1038/ncomms12645. PMID: 27561551

Zhang Y, Sriraman SK, Kenny HA, Luther E, Torchilin V, Lengyel EReversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Mol Cancer Ther. 2016 Oct;15(10):2282-2293. Epub 2016 Jul 27. PMID: 27466355

Fehniger J, Thomas S, Lengyel E, Liao C, Tenney M, Oto A, Yamada SD.A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. Gynecol Oncol. 2016 Jul;142(1):169-75. doi: 10.1016/j.ygyno.2016.04.018. Epub 2016 Apr 28. PMID: 27103176

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: .1038/nrc4019. Review. PMID: 26493647

Litchfield LM, Mukherjee A, Eckert MA, Johnson A, Mills KA, Pan S, Shridhar V, Lengyel E, Romero ILHyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. 2015 Sep 15;6(27):23548-60. PMID: 26172303

Stringer-Reasor EM, Baker GM, Skor MN, Kocherginsky M, Lengyel E, Fleming GF, Conzen SD. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep;138(3):656-62. Epub 2015 Jun 24. PMID: 26115975

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, NonesK, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, HarliwongI, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD. Whole-genome characterization of chemoresistant ovarian cancerNature. 2015 521(7553), 489-94. PMID: 26017449.

Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancerGynecologic Oncology, 2015, 137(3):485-9, PMID 25838164

Kinose Y, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Takahashi K, Kurachi H, Lengyel E, Kimura T. The hypoxia-related microRNA-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget, 2015, 6(13), 11342-56. PMID: 25839163

Kohlhapp F, Mitra AK, Lengyel E, Peter ME microRNAs as mediators and communicators between cancer cells and the tumor micro-environment. Oncogene, 2015, in press 
PMID 25867073

Mitra AK, Chiang CY, Tiwari P, Watters KM, Peter ME, and Lengyel E Microenvironment induced downregulation of miR-193b drives ovarian cancer metastasisOncogene, 2015, in press PMID 25798837

Lengyel E, Litchfield LM, Mitra AK, Nieman KM, Mukherjee A, Zhang Y, Johnson A, Bradaric M, Lee WS, Romero I Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. American Journal of Obstetrics and Gynecology, 2015, 212(4):479.e1-479.e10. PMCID: PMC4387077

King M, Lindberg M, Stodden G, Okuda H, Ebers S, Johnson A, Montag A, Lengyel E, MacLean J, Hayashi K. WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancerOncogene, 2015, 34(26):3452-62. PMID 25174399

Romero IL, Mukherjee A, Kenny HA, Litchfield LM, and Lengyel E. Molecular Pathways: Trafficking of metabolic resources in the tumor microenvironment. Clinical Cancer Research, 2015, 21 (4): 680-686.  PMID 25691772

Kenny HA, Lal-Nag M, White EA, Shen M, Chiang CY, Mitra AK, Zhang Y, Curtis M, Schryver EM, Bettis S, Jadhav A, Boxer MB, Li Z, Ferrer M, and Lengyel E. Quantitive high throughput screening (HTS) using a physiologically-relevant primary human three-dimensional organotypic culture predicts in vivo efficacyNature Communications, 2015, 6:6220. PMID 25653139

Kim JS, Liang MI, Prendergast EN, Alldredge J, Datta A, Hurteau JA, Kirschner CV, Rodriguez G, Vogel TJ, Brooks RA, Cass I, Cohen JG, Penner KR, Wang CE, Diaz Moore ES.Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.Int J Gynecol Cancer. 2019 Sep;29(7):1156-1163. doi: 10.1136/ijgc-2019-000374. Epub 2019 Jul 27.  PMID: 31352365

Hoppenot C, Peters P, Cowan M, Moore ED, Hurteau J, Lee NK, Yamada SD. Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?Gynecol Oncol. 2019 Jul;154(1):177-182. doi: 10.1016/j.ygyno.2019.04.681. Epub 2019 May 2.  PMID: 31056111

Prendergast EN, Holzapfel M, Mueller JJ, Leitao MM Jr, Gunderson CC, Moore KN, Erickson BK, Leath CA 3rd, Diaz Moore ES, Cohen JG, Walsh CS.Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.Gynecol Oncol. 2017 Feb;144(2):274-278. doi: 10.1016/j.ygyno.2016.12.004. Epub 2016 Dec 12.  PMID: 27979319Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer. 
Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782 PMID:28708786

Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME
Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer. 
Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782
PMID:28708786

 

 

Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer.CA Cancer J Clin. 2019 Jul;69(4):258-279. doi: 10.3322/caac.21561. Epub 2019 May 10. Review.  PMID: 31074865

Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1048. [Epub ahead of print]  PMID: 31194228

Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13.  PMID: 29437535

Luke AM, Moroney JW, Snitchler A, Whiteway SL. Ovarian Sertoli-Leydig Cell Tumor with Elevated Inhibin B as a Cause of Secondary Amenorrhea in an Adolescent with Germ Line DICER1 Mutation. J Pediatr Adolesc Gynecol. 2017 Oct;30(5):598-600. doi: 10.1016/j.jpag.2017.05.002. Epub 2017 May 11. PMID: 28502826

Son CH, Fleming GF, Moroney JW.
Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers.
Cancer Manag Res. 2017 Oct 31;9:553-563. doi: 10.2147/CMAR.S116683. eCollection 2017. Review.
PMID:29184441

Luke AM, Moroney JW, Snitchler A, Whiteway SL .Recurrent ovarian Sertoli-Leydig cell tumor; a rare cause of secondary amenorrhea in adolescence.
J Pediatr Adolesc Gynecol. 2017 May 11. pii: S1083-3188(16)30285-6. [Epub ahead of print]
PMID:28502826

Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R.Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
Ann Oncol. 2015 Jul;26(7):1346-52.. Epub 2015 Apr 15.
PMID:25878190

 

Mai PL, Huang HQ, Wenzel LB, Han PK, Moser RP, Rodriguez GC, Boggess J, Rutherford TJ, Cohn DE, Kauff ND, Phillips KA, Wilkinson K, Wenham RM, Hamilton C, Powell MA, Walker JL, Greene MH, Hensley ML.Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. Gynecol Oncol. 2020 Jan;156(1):131-139. doi: 10.1016/j.ygyno.2019.10.026. Epub 2019 Nov 21.  PMID: 31759774

Kim JS, Liang MI, Prendergast EN, Alldredge J, Datta A, Hurteau JA, Kirschner CV, Rodriguez G, Vogel TJ, Brooks RA, Cass I, Cohen JG, Penner KR, Wang CE, Diaz Moore ES. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery. Int J Gynecol Cancer. 2019 Sep;29(7):1156-1163. doi: 10.1136/ijgc-2019-000374. Epub 2019 Jul 27. PMID: 31352365

Kim JS, Turbov J, Rosales R, Thaete LG, Rodriguez GCCombination simvastatin and metformin synergistically inhibits endometrial cancer cell growth. Gynecol Oncol. 2019 Aug;154(2):432-440. doi: 10.1016/j.ygyno.2019.05.022. Epub 2019 Jun 6.  PMID: 31178149

...Robson M, Rodriguez GCMendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 Jul;121(2):180-192. doi: 10.1038/s41416-019-0492-8. Epub 2019 Jun 19. PMID: 31213659

Rodriguez GC, Kauderer J, Hunn J, Thaete LG, Watkin WG, Russell S, Yozwiak M, Basil J, Hurteau J, Lele S, Modesitt SC, Zivanovic O, Zhang HH, Bartels PH, Alberts DS.Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study.Cancer Prev Res (Phila). 2019 Jun;12(6):401-412. doi: 10.1158/1940-6207.CAPR-18-0383. Epub 2019 Apr 23.  PMID: 31015198

… Robson M, Rodriguez GC….
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.
J Natl Cancer Inst. 2018 Oct 12. [Epub ahead of print]
PMID:30312457

…Rennert G, Risch H, Rodriguez GC…
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk.
Cancer Res. 2018 Sep 15;78(18):5419-5430.. Epub 2018 Jul 27.
PMID:30054336

…Rhiem K, Robson M, Rodriguez GC
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
Hum Mutat. 2018 May;39(5):593-620.. Epub 2018 Mar 12.
PMID:29446198

Waheed S, Dorjbal B, Hamilton CA, Maxwell GL, Rodriguez GC, Syed V.
Progesterone and calcitriol reduce invasive potential of endometrial cancer cells by targeting ARF6, NEDD9 and MT1-MMP.
Oncotarget. 2017 Nov 28;8(69):113583-113597. eCollection 2017 Dec 26.
PMID:29371931
….Rhiem K, Richardson A, Rodriguez GC, ….
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.
Nat Genet. 2017 Dec;49(12):1767-1778 Epub 2017 Oct 23.
PMID:29058716

Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME
Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer. 
Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782
PMID:28708786

Phelan CM, Kuchenbaecker KB…Rodriguez GC Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
Nat Genet. 2017 May;49(5):680-691. Epub 2017 Mar 27.
PMID: 28346442

Hamdi Y, Soucy P, Kuchenbaeker KB…Rodriguez GC
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
Breast Cancer Res Treat. 2017 Jan;161(1):117-134. Epub 2016 Oct 28.
PMID: 27796716

Hibler EA, Kauderer J, Greene MH, Rodriguez GC, Alberts DS.
Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study.
Menopause. 2016 Nov;23(11):1228-1232.
PMID:27433858

Bokhari AA, Lee LR, Raboteau D, Turbov J, Rodriguez IV, Pike JW, Hamilton CA, Maxwell GL, Rodriguez GC, Syed V.
Progesterone potentiates the growth inhibitory effects of calcitriol in endometrial cancer via suppression of CYP24A1.
Oncotarget. 2016 Nov 22;7(47):77576-77590. 
PMID:27769055

Lawrenson K, Kar S, McCue K, Kuchenbaeker K…Rodriguez G,
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Nat Commun. 2016 Sep 7;7:12675.
PMID:27601076

Vigorito E, Kuchenbaecker KB... Rodriguez GC
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
PLoS One. 2016 Jul 27;11(7):e0158801. eCollection 2016.
PMID: 27463617

Rodriguez GC, Turbov J, Rosales R, Yoo J, Hunn J, Zappia KJ, Lund K, Barry CP, Rodriguez IV, Pike JW, Conrads TP, Darcy KM, Maxwell GL, Hamilton CA, Syed V, Thaete LG.
Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: An opportunity for chemoprevention.
Gynecol Oncol. 2016 Oct;143(1):159-67. Epub 2016 Jul 29.
PMID: 27106018

Rebbeck TR, Mitra N, Wan F, Sinilnikova…., Rodriguez G,.et. al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 7;313(13):1347-61

Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 (multiple authors) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2015 May 2

Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun;137(3):485-9.

Blanco I, Kuchenbaecker K and multiple authors. Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.PLoS One. 2015 Apr 1;10(4):e0120020

Blanco I, Kuchenbaecker K and multiple authors. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015 Feb;47(2):164-71

Peterlongo P and multiple authors. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):308-16

Yucer N, Holzapfel M, Jenkins Vogel T, Lenaeus L, Ornelas L, Laury A, Sareen D, Barrett R, Karlan BY, Svendsen CN. Directed Differentiation of Human Induced Pluripotent Stem Cells into Fallopian Tube Epithelium. Sci Rep. 2017 Sep 6;7(1):10741. doi: 10.1038/s41598-017-05519-2.  PMID: 28878359

Vogel TJ, Goodman MT, Li AJ, Jeon CY
Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
Gynecol Oncol. 2017 Aug;146(2):340-345. doi: 10.1016/j.ygyno.2017.05.009. Epub 2017 Jun 7.
PMID:28596017

Vogel TJ, Jeon C, Karlan B, Walsh C. Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis. Gynecol Oncol. 2016 Feb;140(2):285-8. doi: 10.1016/j.ygyno.2015.12.003. PubMed PMID: 26691221

Vogel TJ, Knickerbocker A, Shah CA, Schiff MA, Isacson C, Garcia RL, Goff BA. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers. J Gynecol Oncol. 2015 Jan;26(1):25-31. doi: 10.3802/jgo.2015.26.1.25. PubMed PMID: 25376917; PubMed Central PMCID: PMC4302281

Hoppenot C, Peters P, Cowan M, Moore ED, Hurteau J, Lee NK, Yamada SDMalignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?Gynecol Oncol. 2019 Jul;154(1):177-182. doi: 10.1016/j.ygyno.2019.04.681. Epub 2019 May 2.  PMID: 31056111

Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blaženović I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor SM, Andrade J, Fiehn O, Moellering RE, Mann M, Lengyel E. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts.Nature. 2019 May;569(7758):723-728. doi: 10.1038/s41586-019-1173-8. Epub 2019 May 1.  PMID: 31043742

Geospatial patterns of access to self-care resources for obesity among endometrial cancer survivors in a high poverty urban community.Ross JGC, Escamilla V, Lee NK, Diane Yamada S, Lindau ST.Gynecol Oncol. 2019 Feb;152(2):322-327. doi: 10.1016/j.ygyno.2018.12.005. Epub 2018 Dec 20.  PMID: 30581035

Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, Johnson A, Wroblewski K, Montag A, Yamada SD, López-Méndez B, Nilsson J, Mund A, Mann M, Curtis M
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.
Cell. 2018 Sep 20;175(1):159-170.e16. doi: 10.1016/j.cell.2018.08.065.
PMID:30241606

Curtis M, Kenny HA, Ashcroft B, Mukherjee A, Johnson A, Zhang Y, Helou Y, Batlle R, Liu X, Gutierrez N, Gao X, Yamada SD, Lastra R, Montag A, Ahsan N, Locasale JW, Salomon AR, Nebreda AR, Lengyel E.
Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.
Cell Metab. 2018 Aug 28. pii: S1550-4131(18)30508-4. [Epub ahead of print]
PMID:30174305

Cowan M, Suntum T, Olivas AD, Perpich M, Applebaum MA, Lastra RR, Yamada SD.
Second primary rhabdomyosarcoma of the uterine cervix presenting with synchronous ovarian Sertoli-Leydig cell tumor: An illustrative case of DICER1 syndrome.
Gynecol Oncol Rep. 2018 Jun 15;25:94-97. eCollection 2018 Aug.
PMID:30014022

Chapel DB, Yamada SD, Cowan M, Lastra RR.
Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
Gynecol Oncol. 2018 Jun;149(3):570-574. doi: 10.1016/j.ygyno.2018.04.005. Epub 2018 Apr 13.
PMID:29656794

Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, Yamada SD, Abumrad NA, Lengyel E.
Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
Oncogene. 2018 Apr;37(17):2285-2301.. Epub 2018 Feb 5.
PMID 29398710

Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME
Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer. 
Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782
PMID:28708786

Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL.Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr;10(4):255-266. doi: 10.1158/1940-6207.CAPR-16-0281. Epub 2017 Mar 6. PMID: 28264838

Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel E. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 Dec;6(12):1342-1351. Epub 2016 Oct 7. PMID: 27856443

Feng CH, Miller CM, Tenney ME, Lee NK, Yamada SD, Hasan Y.Statin Use Significantly Improves Overall Survival in High-Grade Endometrial Cancer. Int J Gynecol Cancer. 2016 Nov;26(9):1642-1649. PMID:27654261

Fehniger J, Thomas S, Lengyel E, Liao C, Tenney M, Oto A, Yamada SD.A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. Gynecol Oncol. 2016 Jul;142(1):169-75. doi: 10.1016/j.ygyno.2016.04.018. Epub 2016 Apr 28. PMID:27103176

He C, Poon C, Chan C, Yamada SD, Lin W. Nanoscale Coordination Polymers Codeliver Chemotherapeutics and siRNAs to Eradicate Tumors of Cisplatin-Resistant Ovarian Cancer. J Am Chem Soc. 2016 May 11;138(18):6010-9. doi: 10.1021/jacs.6b02486. Epub 2016 May 2. PMID:27088560

He C, Chan C, Weichselbaum RR, Fleming GF, Yamada SD, Lin W Nanomedicine for Combination Therapy of Cancer. EBioMedicine. 2015 May 13;2(5):366-7. doi: 10.1016/j.ebiom.2015.05.013. eCollection 2015 May. No abstract available. 
PMID:26137577

He C, Chan C, Weichselbaum RR, Fleming GF, Yamada SD, Lin W. Nanomedicine for Combination Therapy of Cancer.EBioMedicine. 2015 May 13;2(5):366-7

Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SDPatterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun;137(3):485-9

Kennedy V, Abramsohn E, Makelarski J, Barber R, Wroblewski K, Tenney M, Lee NK, Yamada SD, Lindau ST. Can you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation. Gynecol Oncol. 2015 Apr;137(1):119-24